Anavex Life Sciences Corp (AVXL)

[RedShoulder]

Thursday is a big day for SAVA, and the effects it may have good- bad - or neutral on Anavex's SP.

- On Thursday, July 29th, New Clinical Data for Simufilam to be Featured in a Podium Presentation -

On Thursday, July 29th, at approximately 11 am ET, simufilam will be featured in a live podium presentation at AAIC, including a brief Q&A session. This oral presentation will announce results of an interim analysis on safety and cognition for the first 50 patients with Alzheimer’s disease to complete 9 months of open-label treatment. Scientists for Cassava Sciences will also present biomarker data analyzed from cerebrospinal fluid (CSF) collected from 25 study subjects at baseline and again after completing 6 months of open-label drug treatment, including:

Biomarkers of Alzheimer’s disease: amyloid beta42, total tau, P-tau181

Biomarkers of neurodegeneration: neurogranin, neurofilament light chain (NfL)

Biomarkers of neuroinflammation: YKL-40, sTREM2 and HMGB1

Simufilam (sim-uh-FILL-am) is a proprietary, small molecule (oral) drug that restores the normal shape and function of altered filamin A (FLNA), a scaffolding protein, in the brain. Altered FLNA in the brain disrupts the normal function of neurons, leading to Alzheimer’s pathology, neurodegeneration and neuroinflammation.

We should see a lot of SAVA Vol and SP action starting Thursday after 11:00 et when the data is released. It will be interesting to see how that effects AVXL's SP, if at all.